Foresee Pharmaceuticals receives FDA nod for Camcevi

The Food and Drug Administration has given its stamp of approval to Foresee Pharmaceuticals for Camcevi, 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, that is indicated to treat advanced prostate cancer.

"The approval of Camcevi 42 mg is a significant step toward our mission in improving the standard of care and the lives of patients," said Ben Chien, founder and chairman of Foresee. "It also demonstrates the success of Foresee's pioneering Stabilized Injectable Formulation technology. We want to thank the tireless work from the team and all stakeholders, which has made this approval possible."

Camcevi 42 mg injection is exclusively licensed to Accord BioPharma in the U.S. for commercialization. "Camcevi 42 mg is an important addition to of the rapidly expanding Accord Biopharma oncology portfolio and provides clinicians an important option for the treatment of advanced prostate cancer," said Chrys Kokino, U.S. president of Accord BioPharma specialty products.